What 10 Analyst Ratings Have To Say About Revance Therapeutics
Portfolio Pulse from Benzinga Insights
Revance Therapeutics (NASDAQ:RVNC) received 10 analyst ratings in the last quarter, with 6 bullish, 3 somewhat bullish, and 1 indifferent. The average 12-month price target is $29.8, with a high of $44.00 and a low of $12.00. This target has decreased by 22.94% from the previous average of $38.67.
November 22, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Revance Therapeutics has a majority of positive analyst ratings and a decreased price target of $29.8, suggesting a cautiously optimistic outlook.
The predominance of bullish and somewhat bullish ratings indicates a positive sentiment among analysts, which could lead to increased investor confidence and a potential rise in RVNC's stock price in the short term. However, the decrease in the average price target may temper expectations slightly, hence the importance is not at the maximum. The confidence level is high due to the clear consensus among analysts but not absolute due to the inherent uncertainty in market reactions to analyst ratings.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100